Oramed Pharmaceuticals Inc 8-K, filed Sep 17, 2026
Oramed Pharmaceuticals Inc. (ORMP)
About this 8-K
Oramed Pharmaceuticals Inc filed this 8-K on September 17, 2026, reporting on events of September 15, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
| The Tel Aviv Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below.
Proposal No. 1 - Re-election of Directors.
The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:
| Director Name | For | Against | Abstain | Broker Non-Votes | ||||
| Dr. Daniel Aghion | 12,662,432 | 4,769,203 | 20,234 | 7,538,073 | ||||
| Dr. Miriam Kidron | 13,672,468 | 3,756,991 | 22,410 | 7,538,073 | ||||
| Nadav Kidron | 13,702,335 | 3,729,485 | 20,049 | 7,538,073 | ||||
| Dr. Arie Mayer | 11,784,397 | 5,648,636 | 18,836 | 7,538,073 | ||||
| Yehuda Reznick | 13,687,270 | 3,735,295 | 29,304 | 7,538,073 | ||||
| Benjamin Shapiro | 11,567,510 | 5,859,953 | 24,406 | 7,538,073 |
1
Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm for the 2026 Fiscal Year.
The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2026 fiscal year. The votes were as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 22,243,815 | 2,717,251 | 28,876 | 0 |
Proposal No. 3 - Approval of an Amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan.
The stockholders approved an amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan to increase the total number of shares of common stock, par value $0.012 per share, authorized for issuance under such plan by 3,000,000, to a total of 12,500,000. The votes were as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 11,336,951 | 6,080,695 | 34,223 | 7,538,073 |
Proposal No. 4 - Approval of the Say-on-Pay Proposal.
The stockholders approved, on a non-advisory basis, the compensation of our named executive officers (“say-on-pay vote”). The votes were as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 13,012,163 | 4,394,427 | 45,279 | 7,538,073 |
Proposal No. 5 – Approval of the Say-on-Pay Frequency Proposal.
The stockholders selected every three years as the recommended frequency for future say-on-pay votes. The votes were as follows:
| 1 year | 2 years | 3 years | Abstain | Broker Non-Votes | ||||
| 5,974,499 | 13,929 | 11,377,689 | 85,752 | 7,538,073 |
In light of this result, the Board of Directors of the Company has determined that the Company will hold future say-on-pay votes every three years until the next advisory vote on the frequency of say-on-pay votes, which is required to take place at least once every six years.
Proposal No. 6 - Adjournment Proposal
The proposal to approve the adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Proposals 1 through 5 at the time of the Annual Meeting, was rendered moot as there were sufficient votes to approve the Proposals 1 through 5 at the time of the Annual Meeting.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ORAMED PHARMACEUTICALS INC. | ||
| By: | /s/ Nadav Kidron | |
| Name: | Nadav Kidron | |
| Title: | President and CEO | |
September 17, 2026
3